The Food and Drug Administration has approved a new pill designed to manage persistently high cholesterol levels. This approval introduces a more convenient option for patients who face a high risk of cardiovascular disease and heart attacks.
Unlike traditional cholesterol-lowering injections, Merck’s Lipfendra offers a daily oral alternative. This can simplify the treatment regimen for individuals struggling with high cholesterol, potentially improving adherence to prescribed therapies and overall heart health.

The Future of MAHA in American Health Politics
Insulin Cost Caps Gaining Support Amid Rising Prices
A Personal Journey Through Encephalitis
Low-Cost Medication May Benefit Stroke Survivors
The Complex Debate Over Kratom Use in the U.S.
Florida’s Struggle with Dengue Fever and AI Solutions